key: cord-0971132-kflrkjm3
authors: Bowe, Stephanie; O’Connor, Cathal; Gleeson, Catherine; Murphy, Michelle
title: Reactive infectious mucocutaneous eruption in children diagnosed with COVID‐19
date: 2021-09-20
journal: Pediatr Dermatol
DOI: 10.1111/pde.14801
sha: 916d172684b968794eac129cc73e8955f0627570
doc_id: 971132
cord_uid: kflrkjm3

We describe the cases of two immunocompetent children who developed mucositis with oral, ocular, and genital involvement during acute COVID‐19 illness. The pattern of mucosal involvement with no other cutaneous involvement was consistent with reactive infectious mucocutaneous eruption (RIME). No other intercurrent infections or new medications were identified, suggesting that COVID‐19 was causative. Both patients noted improvement with systemic corticosteroid therapy.

hepatitis C antibody, HIV antibody, syphilis total antibody, and blood cultures were negative, and antistreptolysin O titer was <200 U/mL for both patients. Chest X-ray was normal in both patients.

Following dermatology consultation, both patients were diagnosed with SARS-CoV-2-associated reactive infectious mucocutaneous eruption (RIME).

Both patients were treated with intravenous hydrocortisone (100 mg three times daily for three days), betamethasone valerate 0.1% ointment once daily, hydrocortisone 2.5 mg buccal tablets four times daily, analgesia with paracetamol and ibuprofen, and intravenous hydration. Patient 1 was treated with prednisolone 1% eye drops and was discharged after four days. Due to the severity of Patient 2's oral ulceration, he was given lidocaine hydrochloride mouthwash and received total parenteral nutrition for five days.

Patient 2 was discharged after 14 days once he was able to resume oral intake.

Both patients discontinued treatment at discharge and had complete resolution of mucositis one week after discharge.

Dermatologic manifestations of COVID-19 have been divided into seven clinical patterns: morbilliform, pernio-like, urticarial, macular erythema, vesicular, papulosquamous, and retiform purpura. 1 The term RIME describes the clinical presentation of significant mucositis (oral, ocular, and anogenital) but absent to sparse cutaneous involvement, typically occurring as a late manifestation of exposure to Mycoplasma and other infectious agents such as Chlamydia pneumoniae, metapneumovirus, parainfluenza virus 2, rhinovirus, and enterovirus. The link between RIME and SARS-CoV-2 has not been widely reported, with two cases in adults, 2,3 and one report in a 17-year-old boy. 4 EM has been reported in children with COVID-19, but most cases describe targetoid cutaneous lesions without mucositis. 5 The combination of recent PCR-confirmed SARS-CoV-2 infection, absence of other contemporaneous laboratory-confirmed infections, and prominent mucositis suggests SARS-CoV-2 as an infectious trigger for both patients' RIME. Clinicians should be aware that SARS-CoV-2 can precipitate RIME and that systemic corticosteroids may provide benefit.

This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 

The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries

A case of erythema multiforme major with multiple mucosal involvements in COVID-19 infection

Erythema multiform-like lesions in a patient infected with SARS-CoV-2: a case report

Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection

Skin manifestations of COVID-19 in children: part 2